Back

Title
  • Up-To-Date Perspectives for Hyperuricemia, Cardiorenal Influence and Urate-Lowering Therapy (ULT)
Creator
    • Bando, Hiroshi
Rights
  • This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Subject
  • Other Hyperuricemia
  • Other Urate-Lowering Therapy
  • Other Selective Urate Reabsorption Inhibitor
  • Other Chronic Kidney Disease
  • Other Preventing Early Renal Loss in Diabetes
  • Other American College of Rheumatology
Description
  • Other Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest topics are described. The guideline adequately managing gout was published from American College of Rheumatology (ACR). Various optimal uses of urate-lowering therapy (ULT) were presented. The cardiorenal effects of hyperuricemia have been investigated for years. Regarding the patients on chronic kidney disease (CKD) and high risk of progression, ULT with allopurinol did not show the decline in eGFR compared to the control. Recently, dotinurad that is a new selective urate reabsorption inhibitor (SURI) would be applied to medical practice. Low-dose dotinurad showed satisfactory pharmacological efficacy.
Publisher Asploro
Date
    Issued2021-04-27
Language
  • eng
Resource Type journal article
Version Type VoR
Identifier URI http://repo.lib.tokushima-u.ac.jp/116090
Relation
  • isIdenticalTo DOI https://doi.org/10.36502/2021/droa.6178
Journal
  • Diabetes Research : Open Access
  • Volume Number3 Issue Number1 Page Start16 Page End19
File
Oaidate 2023-06-26